奥氮平合并文拉法新治疗难治性抑郁症对照研究

A Clinical Comparative Study of Olanzapine Combined with Venlafaxine on the Refractory Depression

目的探讨小剂量奥氮平合并文拉法新治疗难治性抑郁症的疗效及安全性。方法将62例难治性抑郁症患者随机分为研究组和对照组,分别给予文拉法新合并小剂量奥氮平治疗及单用文拉法新治疗,疗程8周,以汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评定临床疗效,以副反应量表(TESS)和相关检查评定不良反应。结果治疗结束时两组的HAMD和HAMA评分均较治疗前显著降低,差异有显著性,两组间有效率差异也有统计学意义。研究组和对照组分别有51.5%和41.9%出现不良反应,差异无统计学意义。结论小剂量奥氮平在难治性抑郁症的治疗中有增效作用,优于单用文拉法新,且耐受性好。

Objective To explore the effects of low-dose olanzapine combining with venlafaxine on the refractory depression. Methods 62 patients with refractory depression were randomly assigned to study group （treated with oanzapine and venlafaxine, n=31） and control group （treated with venlafaxine alone, n=31） for 8 weeks, The clinical effect were evaluated with Hamilton Depression Scale （HAMD） and the Hamilton anxiety Scale （HAMA）. Adverse events were assessed by the treatment emergent symptom Scale （TESS） and related laboratory examinations. Results There were significant differences on the scores of HAND and HAMA between the two groups after treatment. The effective rate had significant difference between two groups. 51.5% of patients in study group showed mild side effects, in comparison with 41.9% in control group. Conclusion Olanzapine may be effective and safe in the treatment of refractory depression.